Show simple item record

dc.contributor.authorH Kalanie
dc.contributor.authorS S Tabatabai
dc.date.accessioned2017-10-24T12:17:58Z
dc.date.available2017-10-24T12:17:58Z
dc.identifier.citationrft.volume=39&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.spage=178&rft.issue=3&rft.epage=81&ctx_ver=Z39.88-2004&rft.jtitle=European+neurology&rft.date=1998
dc.identifier.issn0014-3022
dc.identifier.urihttp://dsp.sbmu.ac.ir/xmlui/handle/123456789/80682
dc.description.abstractIn an attempt to prevent exacerbations of multiple sclerosis, immunoglobulin therapy was combined with azathioprine (AZA). Intravenous immunoglobulin (i.v.IG) 2 g/kg was given in divided doses over 3 consecutive days followed by monthly booster doses (0.2 g/kg) for 3 years to 38 patients with relapsing-remitting multiple sclerosis (MS). In the 34 patients who completed the trial, the relapse rate decreased (from 1.7 relapses per year to 0 during the 3-year trial period). The Kurtzke Expanded Disability Status Scale decreased from 3.4 +/- 0.72 to 3.0 +/- 0.70. The results suggest that combined i.v.IG and AZA suppress the ongoing pathologic process in relapsing-remitting MS.
dc.sourceEuropean neurology
dc.titleCombined immunoglobulin and azathioprine in multiple sclerosis.


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record